Roche Expands Metabolic Portfolio with US$3.5bn acquisition of 89bio
tags: 89bio| cardiovascular| healthcare| M&A| MASH| metabolic| pharma| pharmaceutical| Public Market Deals| renal| Roche
Swiss multinational pharma and diagnostics giant Roche has signed a definitive agreement to acquire California-based biotech group 89bio in a deal worth up to US$3.5bn, planning to expand in cardiovascular, renal and metabolic diseases while diversifying beyond oncology and immunology. Roche will pay US$2.4bn upfront, and up to US$3.5bn if certain milestones are hit tied to commercial success / annual sales targets.…